Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest NT$1.1 billion (around $37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products at the company's premises on the Tainan Science Park.
ScinoPharm say it currently has the most number of oncological APIs for the generic industry. "By expanding into the field of oncological injectable formulation, ScinoPharm will be able to provide a vertically integrated, one-stop-shop service for our existing API customers," remarked Jo Shen, president and chief executive of the company.
Current demand of oncology injectables exceeds supply
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze